These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11011983)

  • 1. Intranasal administration of different liquid formulations of bumetanide to rabbits.
    Nielsen HW; Bechgaard E; Twile B; Didriksen E; Sørensen H
    Int J Pharm; 2000 Aug; 204(1-2):35-41. PubMed ID: 11011983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solubilization and stability of bumetanide in vehicles for intranasal administration, a pilot study.
    Nielsen HW; Bechgaard E; Twile B; Didriksen E; Almtorp GT
    Pharm Dev Technol; 2001; 6(2):145-9. PubMed ID: 11416987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arterial and venous blood sampling in pharmacokinetic studies: bumetanide in rabbits.
    Chung SY; Yoon WH; Kim SH; Hwang KS; Lee MG
    Res Commun Mol Pathol Pharmacol; 1997 Dec; 98(3):255-64. PubMed ID: 9485520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits.
    Bechgaard E; Gizurarson S; Hjortkjaer RK
    J Pharm Pharmacol; 1997 Aug; 49(8):747-50. PubMed ID: 9379349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of bumetanide in the newborn infant.
    Lopez-Samblas AM; Adams JA; Goldberg RN; Modi MW
    Biol Neonate; 1997; 72(5):265-72. PubMed ID: 9395836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of the pharmacodynamic differences between immediate and extended release bumetanide formulations.
    Hamed E; Gerson MC; Millard RW; Sakr A
    Int J Pharm; 2003 Nov; 267(1-2):129-40. PubMed ID: 14602391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of bumetanide in critically ill infants.
    Sullivan JE; Witte MK; Yamashita TS; Myers CM; Blumer JL
    Clin Pharmacol Ther; 1996 Oct; 60(4):405-13. PubMed ID: 8873688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol.
    Bagger MA; Nielsen HW; Bechgaard E
    Eur J Pharm Sci; 2001 Aug; 14(1):69-74. PubMed ID: 11457652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced absorption of bumetanide from suppositories containing weak acids in rabbits.
    Yagi N; Kenmotsu H; Shimode Y; Oda K; Sekikawa H; Takada M
    Biol Pharm Bull; 1993 Mar; 16(3):263-7. PubMed ID: 8364470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal absorption of melatonin in vivo bioavailability study.
    Bechgaard E; Lindhardt K; Martinsen L
    Int J Pharm; 1999 May; 182(1):1-5. PubMed ID: 10332069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments.
    Lee SH; Lee MG; Kim ND
    J Pharmacokinet Biopharm; 1994 Feb; 22(1):1-17. PubMed ID: 8027946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasal mucoadhesive delivery systems of the anti-parkinsonian drug, apomorphine: influence of drug-loading on in vitro and in vivo release in rabbits.
    Ikechukwu Ugwoke M; Sam E; Van Den Mooter G; Verbeke N; Kinget R
    Int J Pharm; 1999 Apr; 181(1):125-38. PubMed ID: 10370209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of food on the absorption of frusemide and bumetanide in man.
    McCrindle JL; Li Kam Wa TC; Barron W; Prescott LF
    Br J Clin Pharmacol; 1996 Dec; 42(6):743-6. PubMed ID: 8971430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure.
    Cook JA; Smith DE; Cornish LA; Tankanow RM; Nicklas JM; Hyneck ML
    Clin Pharmacol Ther; 1988 Nov; 44(5):487-500. PubMed ID: 3180632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of probenecid on the dose-response relationship of bumetanide at steady state.
    Lau HS; Shih LJ; Smith DE
    J Pharmacol Exp Ther; 1983 Oct; 227(1):51-4. PubMed ID: 6620171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability and diuretic effect of bumetanide following rectal administration of suppositories containing weak acids in human subjects.
    Yagi N; Kenmotsu H; Shimode Y; Oda K; Sekikawa H; Takada M
    Biol Pharm Bull; 1993 Nov; 16(11):1124-9. PubMed ID: 8312869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-ranging evaluation of bumetanide pharmacodynamics in critically ill infants.
    Sullivan JE; Witte MK; Yamashita TS; Myers CM; Blumer JL
    Clin Pharmacol Ther; 1996 Oct; 60(4):424-34. PubMed ID: 8873690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects.
    Holazo AA; Colburn WA; Gustafson JH; Young RL; Parsonnet M
    J Pharm Sci; 1984 Aug; 73(8):1108-13. PubMed ID: 6491914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and diuretic effect after administration of retarded capsules of bumetanide in human subjects.
    Yagi N; Kiuchi T; Satoh H; Ishikawa Y; Takada M; Sekikawa H
    Biol Pharm Bull; 1999 Mar; 22(3):275-80. PubMed ID: 10220284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of bumetanide in critically ill pediatric patients.
    Marshall JD; Wells TG; Letzig L; Kearns GL
    J Clin Pharmacol; 1998 Nov; 38(11):994-1002. PubMed ID: 9824779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.